In a report released on March 21, Michael Ulz from Morgan Stanley maintained a Sell rating on BioAge Labs, Inc. (BIOA – Research Report), with a price target of $5.00.
Michael Ulz has given his Sell rating due to a combination of factors surrounding BioAge Labs, Inc. The company recently discontinued its lead program, azelaprag, due to safety concerns, specifically the emergence of liver transaminitis. This has led BioAge to focus on developing next-generation APJ agonists, which are still in the early stages of development and have yet to provide substantial clinical data.
Additionally, while BioAge has announced promising collaborations with major companies like Novartis and Lilly, these partnerships are still in the discovery phase and have not yet resulted in concrete outcomes. Despite having a solid cash position expected to last through 2029, the company’s financials showed a significant net loss for the year. These factors contribute to the uncertainty surrounding the company’s future prospects, leading to the Sell rating.
According to TipRanks, Ulz is an analyst with an average return of -5.5% and a 35.21% success rate. Ulz covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Sarepta Therapeutics, and Viking Therapeutics.